Atai Life Sciences could soon become the second psychedelics company to list on a major U.S. exchange.
The Berlin-based biotech firm filed Tuesday with the SEC to raise $100 million in an IPO using the ticker symbol “ATAI.”
The company handles a growing portfolio of about 12 companies, all focused on bringing novel mental health treatments through various technologies. In most cases, these include the use of psychedelic substances in mental health treatment.
Atai also owns about a 25% stake in Compass Pathways (NASDAQ: CMPS), a company developing psilocybin products for psychedelics-assisted psychotherapy, which debuted on Wall Street in September of last year.
A Mental Health Platform Company
Atai works as an umbrella company for a number of mental health startups dedicated to providing alternative solutions to mental health treatment.
The firm, which was founded …
Powered by WPeMatico